TG100-115

DB05552InvestigationalSmall molecule

An NSAID that inhibits PI-3K gamma and delta.

Mechanism: Pharmacologically active on Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform and Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform
Curator reviewed
Primary indication: Investigated for use/treatment in angioedema and myocardial infarction.Curator reviewed
Formula / weight: C₁₈H₁₄N₆O₂ · 346.35 g/mol (avg)
Code names: TG 100-115

Resolves to

Compound

Structure

InChIKeyUJIAQDJKSXQLIT-UHFFFAOYSA-NSMILESNC1=NC(N)=C2N=C(C3=CC=CC(O)=C3)C(=NC2=N1)C1=CC(O)=CC=C1

Targets

What you can answer from here — as of June 12, 2020

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

12+ReferencesStructured and connected to the statements they support

Which drugs share a target with TG100-115, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.